The anti-tumor properties of two tumstatin peptide fragments in human gastric carcinoma

Acta Pharmacologica Sinica

Volumn 30, Issue 9, 2009, Pages 1307-1315

  Li, Ying Jie ^a   Sun, Li Chun ^a   He, Yan ^b   Liu, Xing Han ^b   Liu, Miao ^b   Wang, Qi Min ^b   Jin, Xiao Ming ^b  

^a Medical University   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Anti cancer drug; Apoptosis; Tumstatin peptide

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CASPASE 3; CYSTEINYLASPARAGINYLTYROSYLTYROSYLSERYLASPARAGINYLSERYLTYROSYLSERYLPHENYLALANYLTRYPTOPHANYLLEUCYLALANYLSERYLLEUCYLASPARAGINYLPROLYLGLUTAMYLARGININE; FAS ANTIGEN; FAS LIGAND; METHIONYLPROLYLPHENYLALANYLLEUCYLPHENYLALANYLCYSTEINYLASPARAGINYLVALYLASPARAGINYLASPARTYLVALYLCYSTEINYLASPARAGINYLPHENYLALANYLALANYLSERYLARGINYLASPARAGINYLASPARTYLTYROSYLSERINE; PEPTIDE FRAGMENT; PROTEIN BAX; PROTEIN BCL 2; TUMSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STOMACH CARCINOMA; TUMOR GROWTH; TUMOR VASCULARIZATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOANTIGENS; CELL DIVISION; CELL LINE, TUMOR; COLLAGEN TYPE IV; FEMALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70249104201     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.111     Document Type: Article

References (26)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
2. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257
4. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-288
5. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364
6. Sauer G, Deissler H. Angiogenesis: prognostic and therapeutic implications in gynecologic and breast malignancies. Curr Opin Obstet Gynecol 2003; 15: 45-49
7. Hamano Y, Kalluri R. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem Biophys Res Commun 2005; 333: 292-298
8. MaeshimaY, Colorado PC, Kalluri R. Two RGD-independent αvβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 2000; 275: 23745-23750
9. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000; 275: 21340-21348
10. Mundel TM, Kalluri R. Type IV collagen-derived angiogenesis inhibitors. Microvasc Res 2007; 74: 85-89
11. Maeshima Y, Manfredi M, Reimer C, Holthaus KA, Hopfer H, Chandamuri BR, et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 2001; 276: 15240-15248
12. Maeshima Y, Yerramalla UL, Dhanabal M, Holthaus KA, Barbashov S, Kharbanda S, et al. Extracellular matrix-derived peptide binds to αvβ3 integrin and inhibits angiogenesis. J Biol Chem 2001; 276: 31959-31968
13. Han J, Ohno N, Pasco S, Monboisse JC, Borel JP, Kefalides NA. A cell binding domain from the alpha3 chain of type IV collagen inhibits proliferation of melanoma cells. J Biol Chem 1997; 272: 20395-401.
14. Monboisse JC, Garnotel R, Bellon G, Ohno N, Perreau C, Borel JP, et al. The alpha 3 chain of type IV collagen prevents activation of human polymorphonuclear leukocytes. J Biol Chem 1994; 269: 25475-25482
15. Shahan TA, Fawzi A, Bellon G, Monboisse JC, KefalidesNA. Regulation of tumor cell chemotaxis by type IV collagen is mediated by a Ca2+dependent mechanism requiring CD47 and the integrin alpha(V) beta(3). J Biol Chem 2000; 275: 4796-4802
16. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285
17. Zhu B, Lu L, Cai W, Yang X, Li C, Yang Z, et al. Kallikrein-bindin protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther 2007; 6: 3297-3306
18. Soares AB, Juliano PB, Araujo VC, Metze K, Altemani A. Angiogenic switch during tumor progression of carcinoma ex-pleomorphic adenoma. Virchows Arch 2007; 451: 65-71.
19. Folkman J, Kalluri R. Cancer without disease. Nature 2004; 427:787
20. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003; 3: 422-33.
21. Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995; 1: 120-122
22. Sudhakar A, Boosani CS. Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression. Pharm Res 2008; 25: 2731-2739
23. Cao JG, Peng SP, Sun L, Li H, Wang L, Deng HW. Vascular basement membrane-derived multifunctional peptide, a novel inhibitor of angiogenesis and tumor growth. Acta Biochim Biophys Sin 2006; 38: 514-522
24. Pedchenko V, Zent R, Hudson BG. Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelial cell adhesion. J Biol Chem 2004; 279: 2772-2780
25. Boosani CS, Mannam AP, Cosgrove D, Silva R, Hodivala-Dilke KM, Keshamouni VG, et al. Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis. Blood 2007; 110: 1168-1177
26. Floquet N, Pasco S, Ramont L, Derreumaux P, Laronze JY, Nuzillard JM, et al. The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen(tumstatin) are conformation-dependent. J Biol Chem 2004; 279: 2091-2100